Join
Live feed
·
PRReleasevia Quantisnow
CAMP4 Therapeutics Corporation logo

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

ByQuantisnow·Wall Street's wire, on your screen.
CAMP· CAMP4 Therapeutics Corporation

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CAMP (CAMP4 Therapeutics Corporation) and more on Quantisnow.